Summit Therapeutics

Summit Therapeutics, Inc. a biopharmaceutical company, which discovers, develops, and commercializes medicines to treat infectious diseases. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Menlo Park, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Summit Therapeutics reports strong financials and strategic Akeso partnership

Summit Therapeutics showcased strong financials, promising clinical trial results, and a strategic partnership with Akeso for ivonescimab, positioning the company for growth.
While facing challenges around licensing agreements and international trial data acceptance, Summit's focus on oncology and global collaborations presents opportunities for future success.
With a solid financial foundation, innovative pipeline, and strategic vision, Summit is well-positioned to navigate challenges, capitalize on opportunities, and drive value for stakeholders.

Summit Therapeutics secures $5B deal for ivonescimab, shifts to oncology

Summit Therapeutics made a strategic move with a $5 billion transaction for ivonescimab, signaling a shift towards oncology-focused R&D.
While challenges exist in transitioning away from anti-infectives, Summit's strong financial position and Phase III progress offer promising opportunities.
The company's commitment to innovative therapies and strategic partnerships sets the stage for potential growth and market success.

Summit Therapeutics reports stable finances and progress in Phase III trials

Summit Therapeutics showcased resilience with a strong cash position despite reporting a net loss in Q2 2023.
The company's progress in Phase III trials and positive patient response data offer promise for future growth.
While facing challenges in trial execution and financial pressures, Summit has opportunities to advance its pipeline and attract investor support.

Summit Therapeutics advances ivonescimab in Q3 with strong financials

Summit Therapeutics is making significant strides in advancing ivonescimab for solid tumors, supported by strong financials and strategic partnerships. While facing challenges in differentiation and competitive landscape, the company is well-positioned to seize opportunities for growth and innovation. With a focus on operational excellence and clinical trial progress, Summit remains poised for future success.

Summit Therapeutics excels in Q4 with Ivonescimab progress and challenges

Summit Therapeutics showcased strong performance and financial stability, driven by advancements in Ivonescimab's trials and partnerships.
While facing challenges such as upcoming regulatory actions and timeline constraints, the company remains poised to leverage opportunities for market differentiation and growth.

Summit Therapeutics advances ivonescimab in oncology, eyes Phase III data

Summit Therapeutics made significant progress in Q1 2024, bolstered by strong financials and strategic collaborations. The company's focus on ivonescimab's potential in oncology, along with upcoming data releases, positions it for future success. Managing R&D expenses and leveraging key partnerships will be critical for sustained growth.

Summit Therapeutics advances ivonescimab with strong financial backing and collaborations

Summit Therapeutics made significant progress in clinical trials and regulatory milestones for ivonescimab, supported by strong financials and strategic collaborations.
While facing challenges in data disclosure and operational management, the company has opportunities to drive growth through further trial success and partnerships.
Overall, Summit Therapeutics is well-positioned to capitalize on its strengths and navigate challenges to unlock future opportunities in the competitive biopharmaceutical landscape.
Investors should monitor the company's continued progress in trials, partnerships, and financial management for insights into its long-term growth potential.

Summit Therapeutics advances ivonescimab with strong financial backing and global trials

Summit Therapeutics demonstrated strong performance in advancing ivonescimab, supported by robust financial management and operational efficiency.
While facing challenges in regulatory uncertainties and managing expenses, the company has opportunities to leverage positive trial outcomes and strategic expansions.
Overall, Summit Therapeutics' progress with ivonescimab presents a promising outlook for accelerated development and market growth in diverse tumor settings.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

MENLO PARK, Calif.--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the second quarter and six months ended June 30, 2023. Operational & Corporate Updates Our operational progress with ivonescimab (SMT112), an innovative, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effect.

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023

MENLO PARK, Calif.--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics to host its quarterly Earnings Call on August 9, 2023 at 9:00am ET.

Summit Therapeutics to Host Q2 2023 Financial Results & Operational Progress Call on August 9, 2023

NEW YORK , July 10, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Summit Therapeutics Inc. (NASDAQ: SMMT). If you are a shareholder of Summit Therapeutics Inc. and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at: https://pjlfirm.com/summit-therapeutics-inc/ You may also contact Robert H.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Summit Therapeutics Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

Summit Therapeutics Inc. goes in the spotlight today, as the company has made substantial changes to its developmental focus over the past year. Largely new management has made a "bet the company" move via a huge collaboration deal around a promising oncology asset. Will this wager pay off?  An investment analysis follows in the paragraphs below.

Summit Therapeutics Makes A Leap Of Faith

MENLO PARK, Calif.--(BUSINESS WIRE)---- $SMMT--Promising Data Supporting Summit's Phase III Clinical Trials for Ivonescimab Featured at ASCO 2023.

Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023

MENLO PARK, Calif.--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. The poster with updated clinical data from Phase II clinical trials will be displayed on Sunday June 4 from 8:00 to 11:00am Central Time during the Lung Cancer – Non.

Ivonescimab Updated Data to be Featured at ASCO 2023

Summit's cash position is worrying. The company only has one therapy in clinical trials.

Why Shares of Summit Therapeutics Slumped on Tuesday

MENLO PARK, Calif.--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the first quarter ended March 31, 2023. Operational & Corporate Updates Our Collaboration and License Agreement with Akeso Inc. (Akeso) for ivonescimab: On December 5, 2022, Summit and Akeso entered into a Collaboration and License Agreement for ivonescimab, Akeso's innovative, potentially first.

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023

MENLO PARK, Calif.--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the first United States-based patient has been enrolled in the Phase III HARMONi study. HARMONi is a Phase III multiregional, randomized, double-blinded study. The study will evaluate the efficacy and safety of ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous non-sm.

Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)

The company's current pipeline only includes two drugs. Summit Therapeutics' shares are up more than 93% over the past 12 months.

Why Shares of Summit Therapeutics Soared This Week

MENLO PARK, Calif.--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics announces its initial indications for clinical trials for ivonescimab and its Q1 2023 Earnings Call date and time.

Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (SMT112)

American Assets

AbbVie

Byline Bancorp

Coastal Financial Corp

Clear Channel Outdoor Holdings

Compass Minerals

Enovix Corporation

Heartland Express

iHeartMedia

JELD-WEN Hld

Mineralys Therapeutics Inc

OPKO Health

PacWest Bancorp

Precigen

Paramount Group

Purple Innovation

B. Riley Financial

Cassava Sciences Inc

SPDR S&P 500 ETF Trust

Triumph Financial Inc

LendingTree

Vera Therapeutics

Strong Small-Cap Insider Buys: Q1 2023

Summit Therapeutics is mostly owned by Bob Duggan, who made billions from selling Pharmacyclics. However, Pharmacyclics had something to sell.

Summit Therapeutics: Another Billionaire Project That Isn't Going Anywhere

LOS ANGELES--(BUSINESS WIRE)---- $SMMT #SMMT--The Schall Law Firm Announces it is Investigating Claims Against Summit Therapeutics Inc.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Summit Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm

Summit Therapeutics Inc. (NASDAQ:SMMT ) Q4 2022 Results Conference Call March 9, 2023 9:00 AM ET Company Participants Dave Gancarz - SVP, Corporate Strategy and Stakeholder Relations Dr. Maky Zanganeh - Co-CEO and President Bob Duggan - Chairman and CEO Ankur Dhingra - CFO Conference Call Participants Operator Ladies and gentlemen, thank you for standing by. My name is Brent, and I will be your conference operator today.

Summit Therapeutics Inc. (SMMT) Q4 2022 Earnings Call Transcript

MENLO PARK, Calif.--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics announces its Q4 and year-ended 2022 earnings and will host a conference call at 9am EST today (March 9, 2023).

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022

MENLO PARK, Calif.--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics announces the closing of its fully-subscribed, $500 million rights offering. Summit will also host an earnings call on March 9.

Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering

MENLO PARK, Calif.--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it is nearing the previously-announced expiration date for its rights offering of 5:00 pm Eastern Time on March 1, 2023 (the “Expiration Date”). As a reminder, the subscription price per share shall be equal to the lesser of (i) $1.

Summit Therapeutics' Rights Offering Nearing Expiration Date

MENLO PARK, Calif.--( BUSINESS WIRE )--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that the Company's Board of Directors has set the record date for the Company's previously announced rights offering, which will be available to all holders of record of the Company's common stock, par value $0.01 (the “Common Stock”), as of the close of the market on February 6, 2023 (the “Record Date”).

Summit Therapeutics Announces Timing for Rights Offering for Up to $500 Million

Summit Therapeutics rallied hard off 52-week lows in December after its licensing deal for Ivonescimab was announced. Gains have extended into the new year, which is promising for those seeking to enter long at the current market value.

Summit Therapeutics: Ivonescimab Deal Potential Mid-Term Growth Driver

Cano Health

Carvana

Hall of Fame Resort & Entertainment

Nine Energy Service

PDS Biotechnology Corporation

Rayonier Advanced Materials

Silvergate Capital Corp

TuSimple Holdings

Viking Therapeutics

The fourth quarter of 2022 was relatively better for the stock markets, with the S&P 500 up over 7% (its only positive quarterly return for the year).

5 Best and Worst Performing Small-Cap Stocks in Q4 2022

MENLO PARK, Calif.--( BUSINESS WIRE )--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that we have completed the closing of our previously announced definitive agreement with Akeso Inc. (HKEX Code: 9926.HK, “Akeso”) to in-license its breakthrough bispecific antibody, ivonescimab. Ivonescimab, known as AK112 in China and Australia, and as SMT112 in the United States, Canada, Europe, and Japan, is a novel, potential first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule.

Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody

Alset EHome International

CymaBay Therapeutics

Fate Therapeutics

Century Therapeutics

P3 Health Partners Inc

Avidity Biosciences

Trean Insurance Group

Small-cap stocks usually suffer more than mid- and large-cap stocks when the market as a whole is struggling, and when the market is rallying, they could offer higher returns as well.

5 Best and Worst Performing Small-Cap Stocks in Dec 2022

MENLO PARK, Calif.--( BUSINESS WIRE )--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 09, 2023, at 3:45 PM PST. Robert W. Duggan, Chairman and Chief Executive Officer, and Dr. Maky Zanganeh, Co-Chief Executive Officer and President, will provide details regarding our Company following the announcement of our agreement to in-license the breakthrough innovative bispecific antibody, ivonescimab (SMT112).

Summit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

The clinical-stage biopharma stock has been rising all year.

News for Summit Therapeutics Stock (SMMT)